Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients.
Detailed description
The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients, whether this regimen can improve PFS.
Interventions
DRUGAnlotinib
Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
OTHERConcurrent Chemoradiotherapy
Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
Sponsors
Shandong Cancer Hospital and Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients voluntarily participate in this study, signed informed consent. 2. Patients pathologically diagnosed as locally advanced (IIIB / IV) unresectable non-small cell lung cancer, with measurable lesions; IIIa3 patient: Multiple stations lymph node metastasis detected by mediastinoscope, other lymph node biopsy or PET-CT; IIIa4 patient: Bulky or stable multiple stations N2 lymph node metastasis (Bulky lymph node: short diameter \> 2cm in spiral CT imaging, especially the extranodal invasion); and IIIb patient; T3/4 patient with several ipsilateral or contralateral satellite nodules metastasis will be excluded. 3. Detection of genotypes by providing detectable specimens (tissue) prior to enrollment: patients with negative EGFR mutation, or ALK rearrangement test results. 4. Patients aged between 18 -75 years; with ECOG PS Scoring: 0\ 1 point; with expected survival time\>3 months. 5. Patients with normal organ function within 7 days prior to treatment, the following criteria are met: a) blood routine examination criteria (without blood transfusion in 14 days) : i) hemoglobin (HB) ≥100g/L; ii) white blood cell (WBC)≥ 3.0×10e9/L, absolute neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥100×10e9/L; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min; 6. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50% lower limit of normal (LLN); 7. Lung function evaluation: forced expiratory volume in first second (FEVI)≥1.45L/s.
Exclusion criteria
(Patient meet any criteria as following will be excluded): 1. Patients who had previously used anlotinib hydrochloride capsules; 2. Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer); 3. Patients with empty lung squamous cell carcinoma, or non-small cell lung cancer with hemoptysis (\>20 mL/day); 4. Patients had other malignancies in the past 5 years or currently, except undergone resection and at least 5 years of progression free survival or cured cervical cancer in situ, basal cell carcinoma and superficial bladder tumor; 5. Patients who planned to receive systemic anti-tumor therapy within 4 weeks prior to allocation or during the course of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy, except the immunoregulation agents, such as thymosin and lentinan; 6. Patients with more than common terminology criteria for adverse events (CTC AE) level 1 unmitigated toxicity due to any previous treatment, not including hair loss; 7. Patients have a variety of factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.); 8. Patients with pleural effusion or ascites, causing respiratory syndrome (≥ CTC AE level 2 dyspnea); 9. Patients with any severe and/or uncontrolled disease, including: 1. blood pressure control is not ideal (systolic blood pressure ≥ 150 mmHg, diastolic blood pressure ≥ 100 mmHg); 2. myocardial ischemic or myocardial infarction, arrhythmia (including QTc ≥480 ms) and ≥ 2 levels of congestive heart failure (NYHA classification); 3. active or uncontrollable serious infection (≥CTC AE Level 2 infection); 4. liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need to be treated with antiretroviral therapy; 5. renal failure requires hemodialysis or peritoneal dialysis; 6. history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation; 7. poor control of diabetes (fasting blood glucose \[FBG\]\> 10 mmol/L); 8. urine routine test protein≥++, and confirmed 24 hours urine protein\>1.0 g; 9. patients with a seizure and need treatment; 10. Patients with gastric ulcer; 10. Received a major surgical treatment within 28 days prior to allocation, with a biopsy or a significant traumatic injury; 11. Imaging shows that the tumor has been violated around important vascular or the researchers determine the tumor is likely to invade important blood vessels caused by fatal bleeding during the follow-up; 12. Regardless of the severity, patients with any signs or medical history of bleeding; within 4 weeks prior to allocation, patients with any bleeding events ≥ CTC AE level 3, unhealed wounds, ulcers or fractures; 13. Patients with artery/venous thrombotic occurred within 6 months before allocation, such as cerebrovascular accident (including temporary ischemic attack),deep vein thrombosis and pulmonary embolism; 14. Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders; 15. Patients during pregnancy or lactation period; 16. Patients participated in other anti-tumor drug clinical trials within 4 weeks; 17. According to the determination of researchers, patients were diagnosed with disease which will severely endanger the security of patients or influence the completion of this research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 2 years | Progression Free Survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 2 years | Overall survival |
| ORR | 2 years | Objective Response Rate |
| DCR | 2 years | Disease Control Rate |
Countries
China
Contacts
Primary ContactMing Huan Li, doctor
Backup ContactJINMING YU, doctor
Outcome results
None listed